Acquisition Announced

Eli Lilly and Company acquisition of Merida Biosciences

US$2.9bn consideration

Announced 31 Aug 2026

Advisers

Merida Biosciences

Target

Financial adviser

Eli Lilly and Company

Acquirer

Legal adviser
Target
Merida Biosciences
Acquirer
Eli Lilly and Company
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.